
Equistone's Concept Life Sciences bolts on Aquila Biomedical
Equistone-backed laboratory and consultancy group Concept Life Sciences has acquired pre-clinical contract research organisation Aquila Biomedical.
The acquisition is expected to bolster Concept's discovery capabilities with the addition of Aquila's translational biology offering.
It marks the third bolt-on for the company, which was formed in 2014 through a merger of three Equistone portfolio companies, Peakdale Molecular, Resource & Environment Consultants and Scientific Analysis Laboratories.
The first add-on was laboratory consultants CXR Biosciences in August 2015, followed by pharmaceutical testing business Agenda1 in October 2015.
After the acquisition of Aquila, Concept will employ more than 500 people and is targeting revenues of more than $60m for 2017.
Company
Aquila was founded in 2011 by researchers from the University of Edinburgh. It is a pre-clinical contract research organisation with expertise in immune oncology, immunology and multiplex histology.
People
Equistone Partners Europe – Andi Tomkinson (investment director).
Concept Life Sciences – Michael Fort (chair).
Aquila Biomedical – Stephen Anderton (co-founder).
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater